Chronic cough, defined as a cough persisting for more than eight weeks, presents a diagnostic and therapeutic challenge for clinicians. Despite its prevalence, the approach to chronic cough often lacks a systematic and comprehensive strategy, leading to delayed diagnosis and suboptimal management.
Initially, clinicians should differentiate between cough-variant asthma, gastroesophageal reflux disease, and upper airway cough syndrome, the three most common causes of chronic cough. A comprehensive medical history, physical examination, and judicious use of investigations like spirometry, chest radiographs, and upper gastrointestinal endoscopy can guide diagnosis. Additionally, the role of newer diagnostic modalities, such as impulse oscillometry and laryngeal sensory testing, is expanding.
Treatment should be etiology-specific and patient-centered. Empiric treatment trials can be considered when the diagnosis is uncertain. For cough-variant asthma, inhaled corticosteroids are the mainstay of treatment. Proton pump inhibitors are recommended for gastroesophageal reflux disease-associated cough, while antihistamines and nasal corticosteroids can be used for upper airway cough syndrome. Refractory cases may benefit from neuromodulatory agents like gabapentin and pregabalin.
Recent research has shed light on the phenomenon of cough hypersensitivity syndrome, a condition where cough receptors in the airway become hypersensitive, leading to chronic cough. This has opened new avenues for the development of novel therapeutic agents targeting the cough reflex pathway, such as P2X3 receptor antagonists.
In conclusion, a comprehensive and systematic approach to chronic cough is essential for accurate diagnosis and effective management. Emerging concepts and novel therapeutic agents promise to transform the landscape of chronic cough management in the future. Clinicians need to stay abreast of these developments to provide optimal care for patients with chronic cough.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation